Advertisement
Video ThumbnailVideo Thumbnail
Updated: Feb 10, 2022, 03:30 PM IST

Old drug may protect against COVID-19 lung injury finds study

Lung infection and lung injury were the cause of many deaths in the second wave of COVID-19. Doctors everywhere tried their best to find a drug that cured the lung infection. Now, a new preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory has shown a ray of hope. According to them, an FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs. The results of their study were published in 'JCI Insight'. The study found that the drug disulfiram protected rodents from immune-mediated lung injury in two separate models of this type of injury: infection with the SARS-CoV-2 coronavirus that causes COVID-19, and a lung failure syndrome called TRALI that in rare cases occurs after blood transfusion.

Advertisement

Lung infection and lung injury were the cause of many deaths in the second wave of COVID-19. Doctors everywhere tried their best to find a drug that cured the lung infection. Now, a new preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory has shown a ray of hope. According to them, an FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs. The results of their study were published in 'JCI Insight'. The study found that the drug disulfiram protected rodents from immune-mediated lung injury in two separate models of this type of injury: infection with the SARS-CoV-2 coronavirus that causes COVID-19, and a lung failure syndrome called TRALI that in rare cases occurs after blood transfusion.

Advertisement
Advertisement
Advertisement